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ABSTRACT 
Objective: The study was conducted to analyze the rationality of treatment regimens and thrombosis prophylaxis used in coronary artery 
intervention to compare to guidelines for treatment according to VNHA and recommendation of ACC/AHA at Interventional cardiology in Can Tho 
Central General Hospital. 
Methods: The cross-sectional study was based on the data collected from entire medical records of patients at Interventional cardiology in Can Tho 
Central General Hospital from August 2017 to February 2018. The rationality of the antithrombotic regimen used at the Hospital is assessed 
through criteria such as medical combination, dosage, time to take medicine, clinical trials during the treatment. 
Results: The study found that 95.6% and 90.7% were suitable for medical combination before and after PCI; 100% fit for the use of medicine; and 
100% was suitable for antithrombotic agents and clinical trials during treatment time; in terms of dosage, the result showed that entrance and 
maintenance were 84.9% and 100% for aspirin respectively; 71.7% and 100% for clopidogrel; 100% and 94.7% for ticagrelor; 90.2-92.8% and 
98.1% for enoxaparin; especially, heparin-100% anticoagulant was appropriate to recommend. 
Conclusion: The study showed that treatment regimens and thrombosis prophylaxis in percutaneous coronary intervention at Interventional 
cardiology in Can Tho Central General Hospital were quite suitable compared to the recommendations of the Heart Association. The results from the 
study are a scientific basis for the Hospital to maintain or consider adjustments to improve the quality of treatment, ensure the effectiveness and 
safety of patients. 
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Currently, coronary artery disease tends to increase, in which 
myocardial infarction is serious, dangerous and fatal. In the United 
States, about 1,000,000 people are hospitalized every year for acute 
myocardial infarction and about 200,000 to 300,000 people die before 
hospitalization by acute myocardial infarction and the overall mortality 
rate is about 40 percent [1]. According to statistics of the Vietnam 
National Heart Institute, the rate of hospitalization for acute myocardial 
infarction in 2003 was 4.2%, but in 2007 it increased to 9.1% [2]. 
In coronary artery intervention, the use of antithrombotic agents plays 
an important role in preventing platelet activation process and activating 
clotting factors that may lead to the risk of thrombus. However, the use 
of this medicine can cause blood clotting disorders, increasing the risk of 
bleeding; sometimes, it can be life-threatening. In the age of evidence-
based medicine and the "era of antiplatelet drug", in general with many 
new study applications in the treatment of coronary artery disease and 
coronary artery intervention in particular, Worldwide Heart Association, 
such as ACC/AHA, ESC, and Vietnam National Heart Institute, have also 
issued and continuously updated recommendations on using 
antithrombotic agents. Following to evidence-based recommendations 
will help people use medicine effectively and safely.  
As a first-class hospital under the Ministry of Health, Can Tho 
Central General Hospital is also one of the pioneering units in the 
Mekong Delta region to implement the percutaneous coronary 
intervention technique (PCI-Percutaneous Coronary Intervention) 
from over 5 y. However, there have been no studies comparing the 
current treatment regimen supported by anticoagulant in the 
Hospital with current recommendations. Therefore, the study was 
conducted to analyze the rationality of treatment regimen and 
thrombosis prophylaxis used in coronary artery intervention 
compared with the guidelines of treatment according to Vietnam 
National Heart Institute and recommendations of ACC/AHA. 
MATERIALS AND METHODS 
Research design 
The cross-sectional study was based on the data collected from 
entire medical records of patients at Interventional cardiology in 
Can Tho Central General Hospital from August 2017 to February 
2018. Information regarding antithrombotic agents was synthesized, 
including the active ingredient, medical combination, dosage, time to 
take medicine, clinical trials during the treatment. Based on the 
recommendations of Vietnam Heart Association and American Heart 
Association ACC/AHA [2-8], the study conducted to build a set of 
evaluation criteria to analyze the rationality of regimens used in the 
treatment and thrombosis prophylaxis. 
Synthesize and process data 
The characteristics related to the treatment regimen and thrombosis 
prophylaxis were analyzed "suitable" or “unsuitable” according to 
the recommendations, expressed through frequency and percentage. 
Data was aggregated, processed and analyzed by Microsoft Excel. 
RESULTS 
Combination of antithrombotic agents 
Prior to intervention, 4.4% of cases of medicine combination were 
not consistent with the recommendations, including 2 cases of 
clopidogrel (1.0%), 3 cases of clopidogrel+aspirin+ticagrelor+ 
enoxaparin (1.5%) and 4 cases of clopidogrel+enoxaparin (2.0%). 
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After the intervention, 9.3% of cases were not suitable for 
recommendations, including 2 (1.0%) cases using 
ticagrelor+enoxaparin and 17 (8.3%) cases using clopidogrel 
only+aspirin. In 19 cases of ticagrelor using after the intervention, 
17 cases (8.3%) were combined with aspirin+enoxaparin, and 
mainly for STEMI bodies (11 cases) (table 1) 
 
Table 1: Characteristics of combined medicine use according to clinical characteristics of disease before and after PCI 
Medicine combination* Before intervention After intervention 
UA NSTEMI STEMI Total UA NSTEMI STEMI Total 
n=57 (%) n=37 (%) n=111 (%) n=205 (%) n=57 (%) n=37 (%) n=111 (%) n=205 (%) 
C 1 (1.8) 1 (2.7) – 2 (1.0) – – – 0 (0.0) 
CA 20 (35.1) 8 (21.3) 8 (7.2) 36 (17.6) 6 (10.5) 7 (18.9) 4 (3.6) 17 (8.3) 
CE – – 4 (3.6) 4 (2.0) – – – 0 (0.0) 
TE – – – 0 (0.0) – – 2 (1.8) 2 (1.0) 
CAE 36 (63.2) 27 (73.0) 97 (87.4) 160 (78.1) 47 (82.5) 28 (75.7) 94 (84.7) 169 (82.4) 
ATE – – – 0 (0.0) 4 (7.0) 2 (5.4) 11 (9.9) 17 (8.3) 
CATE – 1 (2.7) 2 (1.8) 3 (1.5) – – – 0 (0.0) 
*C: Clopidogrel; A: Aspirin; E: enoxaparin; T: ticagrelor. 
 
How to take medicine and dosage 
How to take antithrombotic agents in the study was consistent with 
the recommendations in which antiplatelet drug was taken orally 
and anticoagulant was used by injection. 
In the group of antiplatelet drugs, the appropriate dose rates 
differed between active ingredients. For aspirin, cases of non-use or 
doses outside the recommended dose range were inappropriate. The 
ratio of using aspirin with the starting and maintenance doses in 
accordance with the recommendations was 84.9% and 100%, 
respectively. Cases of indicated doses of clopidogrel outside the 
recommended dose range or using in combination with ticagrelor 
were inappropriate. The appropriate rate of clopidogrel was 71.7% 
for the starting dose and 100% for the maintenance dose. Regarding 
to ticagrelor, cases that doses used outside the recommended dose 
range were inappropriate. The recommended starting and 
maintenance doses of ticagrelor were 100% and 94.7%, respectively 
(table 2). 
 
Table 2: Dosage appropriateness of antiplatelet drug before and after using PCI 
Active Disease Starting Maintenance 
Suitable use Unsuitable use Non-use Suitable use Unsuitable use Non-use 
Aspirin UA  n=57 (%) 51 (89.5) – 6 (10.5) 57 (100.0) – – 
NSTEMI  n=37 (%) 33 (89.2) 4 (10.8) – 37 (100.0) – – 
STEMI n=111(%) 90 (81.1) 21 (18.9) – 109 (98.2) – 2 (1.8) 
Total n=205 (%) 174 (84.9) 25 (12.2) 6 (2.9) 203 (99.0) 0 (0.0) 2 (1.0) 
Clopidogrel UA  n=57 (%) 40 (70.2) 17 (29.8) – 53 (93.0) – 4 (7.0) 
NSTEMI n=37 (%) 29 (78.4) 8 (21.6) – 35 (94.6) – 2 (5.4) 
STEMI n=111(%) 78 (70.3) 33 (29.7) – 98 (88.3) – 13 (11.7) 
Total n=205 (%) 147 (71.7) 58 (28.3) 0 (0.0) 186 (90.7) 0 (0.0) 19 (9.3) 
Ticargrelor UA  n=57 (%) – – 57 (100.0) 4 (7.0) – 53 (93.0) 
NSTEMI n=37 (%) 1 (2.7) – 36 (97.3) 2 (5.4) – 35 (94.6) 
STEMI n=111(%) 2 (1.8) – 109 (98.2) 12 (10.8) 1 (0.9) 98 (88.3) 
Total n=205 (%) 3 (1.5) 0 (0.0) 202 (98.5) 18 (8.8) 1 (0.5) 186 (90.7) 
 
For the anticoagulant group, the research was also noted differences 
in dose suitability between enoxaparin and heparin. Enoxaparin-
prescribed cases included intravenous injections of 30 mg for those 
under 75 y of age, with a 90.2% recommended compliance rate, and 
subcutaneous injection, including STEMI and maintenance doses for 
all three clinical forms of coronary artery disease, with appropriate 
rates as recommended, were 92.8% and 98.1%, respectively (table 
3). In the meantime, all cases in the research sample conducted PCI 
were assigned appropriate recommended heparin dose in the range 
of 70-100 UI/kg and were conducted aPPT test. 
 
Table 3: Dosage appropriateness of enoxaparin before and after using PCI 
How to take medicine 
and dosage 
Time Disease Recommended Unrecommended Suitability* 
Use Non-use Use Non-use Have Do not have 
Slow I. V 30 mg Staring UA  n=57 (%) 49 (86.0) 8 (14.0) – – 49 (86.0) 8 (14.0) 
NSTEMI  n=37 (%) 32 (86.5) 5 (13.5) – – 32 (86.5) 5 (13.5) 
STEMI  n=111(%) 86 (77.5) 7 (6.3) – 18 (16.2) 104 (93.7) 7 (6.3) 
Total  n=205 (%) 167 (81.5) 20 (9.8) – 18 (8.7) 185 (90.2) 20 (9.8) 
Subcutaneous 
1 mg/kg  
(<75 y old) 
0,75 mg/kg 
(≥ 75 y old) 
Starting STEMI  n=111(%) 103 (92.8) 8 (7.2) – – 103 (92.8) 8 (7.2) 
Maintenance UA  n=57 (%) 51 (89.5) – – 6 (10.5) 57 (100.0) 0 (0.0) 
NSTEMI  n=37 (%) 30 (81.1) – – 7 (18.9)  37 (100.0) 0 (0.0) 
STEMI  n=111 (%) 107 (96.4) 4 (3.6) – – 107 (96.4) 4 (3.6) 
Total n=205 (%) 188 (91.7) 4 (1.9) – 13 (6.4) 201 (98.1) 4 (1.9) 
*Suitability was considered by each clinical form and the total number of patients in the sample 
 
Time to take medicine and treatment monitor 
The time for patients used prescribed anticoagulant ranged from 
2 to 8 d from the time of intervention when enoxaparin was 
discontinued. All cases were monitored for drug use, weight 
determination, AP measurement, liver function test, kidney 
function, hematological test, platelet test, following bleeding 
complications during treatment, and undesirable effects on the 
stomach (risk of inflammation, peptic ulcer, gastrointestinal 
bleeding). 
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DISCUSSION 
The study analyzed the rationality of some key characteristics related 
to the treatment regimen and thrombosis prophylaxis in coronary 
artery intervention compared with the current recommendations at 
the Interventional Cardiovascular Disease Unit in Can Tho Central 
General Hospital in the period of 08/2017-02/2018. 
The types of medicine combination in the study sample were 
consistent with the recommendations of the AHA/ACC and 
guidelines of the Vietnam Cardiology Association that included the 
combination of 2 antiplatelet drugs (aspirin+clopidogrel/ticagrelor) 
and combination of 2 antiplatelet drugs with an anticoagulant 
(enoxaparin) and indications for additional heparin for intervention. 
There were 2 cases of clopidogrel or 3 cases of combination of 
clopidogrel+aspirin+ticagrelor+enoxaparin that had not been 
mentioned in recommendations and treatment guidelines [2-8]. The 
combination of clopidogrel+aspirin+enoxaparin (CAE) was indicated 
mainly for all three clinical forms-UA, NSTEMI, STEMI, with the rates 
of 63.2%, 73.0%, 87.4% respectively before the intervention and 
82.5%, 75.7%, 84.7% after PCI intervention. This result was 
relatively consistent with many other related studies conducted in 
Vietnam [9-11]. Many studies had demonstrated the benefits of 
combining aspirin with a P2Y12 receptor inhibitor for the treatment 
of coronary artery disease, paving the way for a new era in the 
treatment of acute coronary syndrome. This oral dual antiplatelet 
therapy enhanced the antiplatelet effect, played an important role in 
reducing ischemic events, improving prognosis, and reducing 
mortality in patients with coronary artery pathology [12]. The study 
recorded that 17 cases (8.3%) after using dual antiplatelet therapy 
between aspirin+ticagrelor and 186 cases (90.7%) combined with 
aspirin+clopidogrel, mainly for STEMI and PCI cases. 
Regarding the dose of aspirin, there were 31 cases (15.1%) of not 
complying with the recommendations, in which 12 patients were 
prescribed with a dose of 400 mg to 648 mg. Specifically, cases used 
Duoplavin (clopidogrel 75 mg+aspirin 100 mg) before the 
intervention, if they used 4 Duoplavin tablets, they would ensure to 
be suitable for the recommended dose of clopidogrel (300 mg). 
However, the dose of aspirin (400 mg) was higher than 
recommended. Using aspirin at doses higher than 400 mg was 
recorded in 4 cases with 486 mg (324 mg+162 mg or 162 mg+324 
mg) and 1 case with 648 mg (324 mg+324 mg). These cases had 
been recorded using aspirin at doses of 162 mg or 324 mg in the 
previous glands when they moved to the hospital and were assigned 
additional doses of aspirin 162 mg or 324 mg. In addition, the 
results showed that 100% of the maintenance dose of aspirin was 
suitable for the recommendations, which was equivalent to or 
higher than in relevant studies in Vietnam [10, 11]. For clopidogrel, 
the dosage designation that was appropriate for the defect before 
and after intervention was 71.7% and 100%, respectively. 
Compared with the related studies, the study noted a difference in 
using clopidogrel at different hospitals [9-11]. With important 
limitations of clopidogrel such as individualized response and 
irreversible platelet suppression [12], ticagrelor was considered an 
alternative method to optimize antiplatelet therapy in acute 
coronary syndrome, especially in the moderate and high-risk cases 
[12]. However, at the hospital, the number of patients prescribed 
ticagrelor was low, the level of the suitable recommendation was 
100% (3/3 cases) for the starting dose and 94.7% (18/19 cases) for 
maintenance dose. This is also consistent with the research results 
of Nurâ€™aminH. W. et al.: Clopidogrel had a higher risk of MACE 
compared to clopidogrel in patients with CHD after PCI, but there 
were no significant differences in the risk of repeat 
revascularization, myocardial infarction [13]. 
The cases of using enoxaparin in the sample had a high proportion of 
recommended doses according to the similar studies [10], with 
90.2% and 92.8%, respectively, with 30 mg intravenous injection 
doses for patients under 75 y old and subcutaneous dose for STEMI 
cases; and 98.1% for maintenance doses administering 
subcutaneously. Alam, S. et al. said that: In patients with 
CONCLUSION 
unstable 
angina (UA)/non-ST-elevation myocardial infarction (NSTEMI), 
enoxaparin was found to be most widely prescribed low molecular 
weight heparin (LMWH) among other available alternatives. 
However, economic assessment considered fondaparinux as cost-
saving therapeutic agent for initial conservative management of 2-8 
d, added financial benefits over current therapies in the treatment of 
UA/NSTEMI. In fact, at the Can Tho Central General Hospital, the 
form of enoxaparin was available as an injection solution of 4000 
UI/0.4 ml and 6000 UI/0.6 ml, so it was difficult to clinically 
withdraw the exact amount of enoxaparin at the recommended dose 
of 1 mg/kg or 0.75 mg/kg. The dose of enoxaparin ranged from 30 
mg-90 mg corresponding to the injection volume of 0.3 ml-0.9 ml, in 
which the dose of 30 mg corresponding to a volume of 0.3 ml was 
the previous intravenous bolus dose before intervention without 
weight; the remaining cases ranged from 40 mg-90 mg depending on 
the weight of the patient. Based on the peak concentration of Xa-
factor resistance of 0.2 IU/ml and 0.4 IU/ml after subcutaneous 
enoxaparin injection of 20 mg and 40 mg respectively, the dose of 
enoxaparin used for patients was assessed through Xa, to ensure 
Xa>0.5 IU/ml in blood during PCI [14]. It was recommended that 
heparin was administered intravenously during coronary artery 
intervention, was transfer anticoagulant veins in acute coronary 
syndrome and appoint a heparin dose of 60 to 100 UI/kg, in case of 
coronary artery intervention according to the program, the dose of 
60 UI/kg can be used [1, 14]. Through surveys, all cases in the 
sample conducted PCI was indicated by intravenous heparin doses 
in the range of 70-100 UI/kg and were available for testing aPPT. 
Regarding to time to take medicine, the study noted the compliance 
with the recommendations of the anticoagulant group [2-8], 
specifically enoxaparin was indicated from 2 to 5 d after the 
intervention; heparin only injected intravenously dose 60-100 
UI/kg, if the intervention time was over 1 hour that would be 
considered to inject another dose of heparin during the intervention 
depending on treatment experience and patient, no heparin was 
indicated after intervention. The antiplatelet drug group was 
indicated for longer treatment [15], the study was only conducted 
during the time the patient was hospitalized, so there is no basis to 
evaluate the appropriateness of time using as recommended. 
This is one of the first studies conducted at Interventional 
Cardiology in Can Tho Central General Hospital in relation to 
evaluate the rationality of antithrombotic regimen being used with 
recommendations of Cardiovascular Associations. The research 
showed that the use of antithrombotic agents at the Hospital is quite 
appropriate, from which the Hospital can maintain or consider 
adjusting to continue improving the quality of treatment, ensuring 
effectiveness and safety for patients. 
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